Source 1primary paper2025MED
Toolkit/virus-specific T cell therapies
virus-specific T cell therapies
Also known as: VSTs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Additionally, VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Usefulness & Problems
Why this is useful
Virus-specific T cell therapies are presented as cellular therapies directed against specific transplant-associated viruses. The abstract names BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus as targets.; refractory viral infections in transplant recipients; targeting BK virus; targeting cytomegalovirus; targeting Epstein-Barr virus; targeting adenovirus
Source:
Virus-specific T cell therapies are presented as cellular therapies directed against specific transplant-associated viruses. The abstract names BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus as targets.
Source:
refractory viral infections in transplant recipients
Source:
targeting BK virus
Source:
targeting cytomegalovirus
Source:
targeting Epstein-Barr virus
Source:
targeting adenovirus
Problem solved
They are intended to address refractory viral infections in transplant recipients.; management of opportunistic and refractory viral infections in transplant recipients
Source:
They are intended to address refractory viral infections in transplant recipients.
Source:
management of opportunistic and refractory viral infections in transplant recipients
Problem links
management of opportunistic and refractory viral infections in transplant recipients
LiteratureThey are intended to address refractory viral infections in transplant recipients.
Source:
They are intended to address refractory viral infections in transplant recipients.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
antigen-specific t cell recognitionTechniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
The abstract does not provide manufacturing details for generic VSTs.
The abstract does not provide detailed efficacy limits by virus or long-term safety data.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Virus-specific T cell therapies targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation.
Clinical trials demonstrated the safety and feasibility of ex vivo-expanded Tregs in kidney and liver transplantation
Ex vivo-expanded Tregs in kidney and liver transplantation were associated with reduced rejection rates and lower infection risks.
supporting reduced rejection rates and lower infection risks
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Third-party off-the-shelf and multivirus-specific T cells allow faster availability and standardized scalable manufacturing compared to conventional virus-specific T cells.
Advances in third-party, "off-the-shelf" and multi-VSTs allow faster availability and standardized, scalable manufacturing compared to conventional VSTs.
Treg-based therapies including polyclonal Tregs, donor antigen-reactive Tregs, and CAR-Tregs are being studied to minimize conventional systemic immunosuppression while preventing graft rejection.
Treg-based therapies, including polyclonal Tregs, donor antigen-reactive Tregs (darTregs), and chimeric antigen receptor Tregs (CAR-Tregs) are being studied to minimize conventional, systemic immunosuppression while preventing graft rejection.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug virus-specific-t-cell-therapies
Additionally, VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Source:
application scopesupports
Virus-specific T cell therapies targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
VSTs targeting BK virus, cytomegalovirus, Epstein-Barr virus, and adenovirus offer a novel approach for refractory viral infections in transplant recipients.
Source:
field limitationsupports
Further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns for cellular therapies in transplantation.
To establish their role in clinical transplantation, further research is needed to optimize dosing and manufacture, improve antigen specificity, and address long-term safety concerns.
Source:
Comparisons
Source-stated alternatives
The source contrasts VSTs with Treg-based therapies, which are aimed at immune tolerance and rejection rather than antiviral control.
Source:
The source contrasts VSTs with Treg-based therapies, which are aimed at immune tolerance and rejection rather than antiviral control.
Source-backed strengths
novel approach for refractory viral infections
Source:
novel approach for refractory viral infections
Ranked Citations
- 1.